Use of cariprazine in psychiatric disorders: A systematic review

BACKGROUND: Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States. We systematically reviewed the litera­ture on the efficacy and safety of cariprazine.

METHODS: We performed a literature search of the PubMed, MEDLINE, PsycINFO, EMBASE, and Cochrane collaboration databases through August 31, 2016. The search was not restricted by patient age. Articles pub­lished in English or official English translations were included.

RESULTS: Eleven articles that evaluated the use of cariprazine in the treat­ment of psychiatric disorders were identified. Four trials evaluated the safety and efficacy of cariprazine in bipolar disorder. One trial investi­gated its use as an adjunct to antidepressants in major depressive disor­der. Three trials evaluated its use in the treatment of acute exacerbations of schizophrenia. Two studies used risperidone or aripiprazole as com­parators. Both low- and high-dose cariprazine were more effective than placebo in the treatment of acute mania, mixed episodes, and acute psy­chosis. Additionally, cariprazine showed efficacy as an adjunctive treat­ment for depression.

CONCLUSIONS: Our review indicates that cariprazine demonstrates supe­rior efficacy and good tolerability, both at low and high doses, in the treat­ment of individuals with psychosis, mania, and depression.

Purchase this article:


For unlimited access to all issues and articles: